Navari RM - Search Results

1

Selective photocrosslinking of functional ligands to antibodies via the conserved nucleotide binding site.

Alves NJ, Champion MM, Stefanick JF, Handlogten MW, Moustakas DT, Shi Y, Shaw BF, Navari RM, Kiziltepe T, Bilgicer B. Alves NJ, et al. Among authors: navari rm. Biomaterials. 2013 Jul;34(22):5700-10. doi: 10.1016/j.biomaterials.2013.03.082. Epub 2013 Apr 16. Biomaterials. 2013. PMID: 23601661

2

Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo.

Kiziltepe T, Ashley JD, Stefanick JF, Qi YM, Alves NJ, Handlogten MW, Suckow MA, Navari RM, Bilgicer B. Kiziltepe T, et al. Among authors: navari rm. Blood Cancer J. 2012 Apr;2(4):e64. doi: 10.1038/bcj.2012.10. Epub 2012 Apr 20. Blood Cancer J. 2012. PMID: 22829966 Free PMC article.

3

The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice.

Suckow MA, Gutierrez LS, Risatti CA, Wolter WR, Taylor RE, Pollard M, Navari RM, Castellino FJ, Paoni NF. Suckow MA, et al. Among authors: navari rm. Cancer Lett. 2004 Jun 25;209(2):165-9. doi: 10.1016/j.canlet.2004.01.007. Cancer Lett. 2004. PMID: 15159018

4

Cathepsin E is a specific marker of dysplasia in APC mouse intestine.

Busquets L, Guillen H, DeFord ME, Suckow MA, Navari RM, Castellino FJ, Prorok M. Busquets L, et al. Among authors: navari rm. Tumour Biol. 2006;27(1):36-42. doi: 10.1159/000090154. Epub 2005 Dec 8. Tumour Biol. 2006. PMID: 16340248

5

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Navari RM, Nagy CK, Gray SE. Navari RM, et al. Support Care Cancer. 2013 Jun;21(6):1655-63. doi: 10.1007/s00520-012-1710-6. Epub 2013 Jan 12. Support Care Cancer. 2013. PMID: 23314603 Clinical Trial.

6

An accompanying genetic severe deficiency of tissue factor protects mice with a protein C deficiency from lethal endotoxemia.

Castellino FJ, Donahue DL, Navari RM, Ploplis VA, Walsh M. Castellino FJ, et al. Among authors: navari rm. Blood. 2011 Jan 6;117(1):283-9. doi: 10.1182/blood-2010-07-299057. Epub 2010 Sep 21. Blood. 2011. PMID: 20858853 Free PMC article.

7

Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists.

Navari RM. Navari RM. Support Cancer Ther. 2004 Jan 1;1(2):89-96. doi: 10.3816/SCT.2004.n.002. Support Cancer Ther. 2004. PMID: 18628185

8

Blood component therapy in trauma guided with the utilization of the perfusionist and thromboelastography.

Walsh M, Thomas SG, Howard JC, Evans E, Guyer K, Medvecz A, Swearingen A, Navari RM, Ploplis V, Castellino FJ. Walsh M, et al. Among authors: navari rm. J Extra Corpor Technol. 2011 Sep;43(3):162-7. J Extra Corpor Technol. 2011. PMID: 22164456 Free PMC article. Review.

9

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.

Navari RM. Navari RM. Eur J Pharmacol. 2014 Jan 5;722:180-6. doi: 10.1016/j.ejphar.2013.08.048. Epub 2013 Oct 21. Eur J Pharmacol. 2014. PMID: 24157985 Review.

10

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.

Navari RM, Gray SE, Kerr AC. Navari RM, et al. J Support Oncol. 2011 Sep-Oct;9(5):188-95. doi: 10.1016/j.suponc.2011.05.002. Epub 2011 Sep 24. J Support Oncol. 2011. PMID: 22024310 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters